Influenza Virus Vaccine for the 2009-2010 Season

Cumulative 2009/2010 Season Lot Release Status (Updated 8/19/2009)
Flu vaccine lots that have been released by FDA and are available for distribution by the manufacturers. For information on flu vaccine distribution schedules, please contact the manufacturers directly.

Vaccine & Manufacturer	Total number of Lots Released by FDA
AFLURIA CSL Limited	34
FluLaval ID Biomedical Corp. of Quebec	5
FluMist MedImmune, LLC	27*
Fluvirin Novartis Vaccines and Diagnostics Limited	17
Fluzone Sanofi Pasteur, Inc.	47

*Note:  FluMist (MedImmune, LLC) had 14 lots released as of 8/5/2009, not 23 lots as previously reported.

FDA's Vaccines and Related Biological Products Advisory Committee (VRBPAC) met in Silver Spring, Maryland, on February 18, 2009, to select the influenza virus strains for the composition of the influenza vaccine for use in the 2009-2010 U.S. influenza season. During this meeting, the advisory panel reviewed and evaluated the surveillance data related to epidemiology and antigenic characteristics, serological responses to 2008/2009 vaccines, and the availability of candidate strains and reagents.

The panel recommended that vaccines to be used in the 2009-2010 influenza season in the U.S. contain the following:

• an A/Brisbane/59/2007 (H1N1)-like virus; *
• an A/Brisbane/10/2007 (H3N2)-like virus; **
• a B/Brisbane/60/2008-like virus.

*A/Brisbane/59/2007 is a current vaccine virus; A/South Dakota/6/2007 (an A/Brisbane/59/2007-like virus) is a current vaccine virus used in live attenuated vaccines.
**A/Brisbane/10/2007 and A/Uruguay/716/2007 (an A/Brisbane/10/2007-like virus) are current vaccine viruses.

The influenza vaccine composition to be used in the 2009-2010 influenza season in the U.S. is identical to that recommended by the World Health Organization on February 12, 2009, for the Northern Hemisphere's 2009-2010 influenza season.